TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-18

Archived explainer. For the current picture see today's RARE page.

Why Is ULTRAGENYX PHARMACEU (RARE) Stock Up Today?

By the Top Tier Newswire AI Desk · November 18, 2026 at 12:20 AM ET · reviewed against 3 wire stories

ULTRAGENYX PHARMACEU (RARE) is up +5.03% in the latest session. Our newswire has captured 3 stories on RARE across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 45/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Ultragenyx Pharmaceutical (RARE) shares rose 5.03% to close at $16.70. The primary driver for the move was a presentation at the UBS Global Biopharma Conference, where management outlined 2027 financial targets and operational outlooks.

What Happened

The company participated in the UBS Global Biopharma Conference on November 16, 2026. During the session, executives, including founder Emil Kakkis, discussed the firm's strategic direction and upcoming milestones. A key catalyst for investor interest was the announcement that the UK Medicines and Healthcare products Regulatory Agency accepted the marketing authorisation application for rebisufligene etisparvovec.

On the sell side, Guggenheim lowered its price target on the stock to $24 from $35 while maintaining a Buy rating. Leerink Partners also maintained a Buy rating with a $33 price target. These actions reflect a mixed but generally positive sentiment among analysts regarding the company's long-term potential, despite the recent valuation adjustments.

What The Data Shows

Fundamentals indicate a market cap of $1.6 billion for a company that remains unprofitable, with trailing twelve-month earnings per share of negative $5.18. Revenue grew 15.8% over the same period, though the net margin stands at negative 71.8%. The stock has a beta of 0.36 and trades within a 52-week range of $12.73 to $39.89.

Recent trading activity shows the stock gained 8.2% over the last eight sessions, moving from $15.43 to $16.70. The 52-week tape recorded 17 fresh highs and one fresh low on November 17, 2026. Insider activity over the last 90 days includes three sales totaling $128,000, with no buys recorded. The most recent insider sale was filed on October 19, 2026, by CFO Howard Horn. Congressional disclosures show two buys and no sells in the same period, with the most recent filing on October 12, 2026.

What To Watch

Investors will monitor the company's upcoming participation in other investor conferences as it continues to outline its operational outlook. The market will also watch how the stock reacts to the UK regulatory acceptance and whether the recent price target adjustments from major banks influence broader institutional positioning.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

RARE by the numbers

Last: $16.70Session: +5.03%7 sessions: +8.23%Coverage: 3 stories / 3 sourcesAI sentiment: 45/100 (mixed)Mkt cap: $1.6B52w: $12.73 to $39.89
RARE · Nov 18 session (5-min) · +6.24% vs prior close · updated 8:53 PM ET
$16.63$17.26$17.89prev close $16.70$17.747:05 AM9:57 AM12:50 PM3:42 PM6:35 PM7:05 AM · $16.808:00 AM · $16.759:25 AM · $16.759:30 AM · $17.059:35 AM · $17.299:40 AM · $17.189:45 AM · $17.039:50 AM · $17.139:55 AM · $17.2210:00 AM · $17.2510:05 AM · $17.2110:10 AM · $17.3310:15 AM · $17.4710:20 AM · $17.5310:25 AM · $17.5210:30 AM · $17.4610:35 AM · $17.3810:40 AM · $17.3410:45 AM · $17.2710:50 AM · $17.3710:55 AM · $17.3911:00 AM · $17.3511:05 AM · $17.2811:10 AM · $17.2811:15 AM · $17.2711:20 AM · $17.3011:25 AM · $17.3211:30 AM · $17.3311:35 AM · $17.2611:40 AM · $17.3411:45 AM · $17.1911:50 AM · $17.2111:55 AM · $17.2912:00 PM · $17.3412:05 PM · $17.4312:10 PM · $17.5312:15 PM · $17.5412:20 PM · $17.5712:25 PM · $17.5512:30 PM · $17.5812:35 PM · $17.5512:40 PM · $17.6012:45 PM · $17.5912:50 PM · $17.6312:55 PM · $17.611:00 PM · $17.611:05 PM · $17.641:10 PM · $17.681:15 PM · $17.691:20 PM · $17.701:25 PM · $17.701:30 PM · $17.711:35 PM · $17.731:40 PM · $17.671:45 PM · $17.651:50 PM · $17.631:55 PM · $17.632:00 PM · $17.582:05 PM · $17.522:10 PM · $17.452:15 PM · $17.482:20 PM · $17.452:25 PM · $17.432:30 PM · $17.382:35 PM · $17.352:40 PM · $17.392:45 PM · $17.392:50 PM · $17.512:55 PM · $17.513:00 PM · $17.553:05 PM · $17.533:10 PM · $17.573:15 PM · $17.623:20 PM · $17.623:25 PM · $17.623:30 PM · $17.613:35 PM · $17.593:40 PM · $17.643:45 PM · $17.613:50 PM · $17.663:55 PM · $17.744:00 PM · $17.734:25 PM · $17.734:30 PM · $17.826:10 PM · $17.736:35 PM · $17.74
AI sentiment, last 36h · averaged over 3 stories · 45/100 bearish
AI sentiment 45/100 (bearish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishGuruFocus · sentiment 50 · Ultragenyx Pharmaceutical Inc. at UBS Global Biopharma Conference TranscriptGuruFocus · 50Ultragenyx Pharmaceutical Inc. at UBS Global Biopharma Conference TranscriptSeeking Alpha · sentiment 52 · Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha · 52Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Tr…The Fly · sentiment 34 · Ultragenyx price target lowered to $24 from $35 at GuggenheimThe Fly · 34Ultragenyx price target lowered to $24 from $35 at Guggenheim
3d agoThe FlyBEARISH 34Analyst

Ultragenyx price target lowered to $24 from $35 at Guggenheim

3d agoSeeking AlphaNEUTRAL 52Product/PR

Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) UBS Global Biopharma Conference 2026 November 16, 2026 9:00 AM ESTCompany ParticipantsEmil Kakkis - Founder,...

3d agoGuruFocusNEUTRAL 50General

Ultragenyx Pharmaceutical Inc. at UBS Global Biopharma Conference Transcript

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on RARE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier RARE move explainers: 2026-11-18 · 2026-10-07 · 2026-09-22 · 2026-09-18 · 2026-09-17 · 2026-09-04 · 2026-09-03